Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis Ruderman EM; Pope RMArthritis Res Ther 2005[]; 7 Suppl 2 (Suppl 2): S21-5Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.|Abatacept[MESH]|Animals[MESH]|Antigen Presentation[MESH]|Antigens, CD[MESH]|Antigens, Differentiation/genetics/immunology[MESH]|Antirheumatic Agents/pharmacology/*therapeutic use[MESH]|Arthritis, Experimental/drug therapy/immunology[MESH]|Arthritis, Rheumatoid/*drug therapy/immunology[MESH]|Autoimmune Diseases/*drug therapy/immunology[MESH]|B7-1 Antigen/*immunology[MESH]|B7-2 Antigen/immunology[MESH]|CD28 Antigens/*immunology[MESH]|CTLA-4 Antigen[MESH]|Clinical Trials, Phase II as Topic[MESH]|Clinical Trials, Phase III as Topic[MESH]|Double-Blind Method[MESH]|Drug Evaluation, Preclinical[MESH]|Female[MESH]|Humans[MESH]|Immunoconjugates/pharmacology/*therapeutic use[MESH]|Immunoglobulin Fc Fragments/genetics/immunology[MESH]|Lymphocyte Activation/*drug effects[MESH]|Male[MESH]|Mice[MESH]|Middle Aged[MESH]|Multicenter Studies as Topic[MESH]|Pilot Projects[MESH]|Protein Structure, Tertiary[MESH]|Receptors, Antigen, T-Cell/immunology[MESH]|Recombinant Fusion Proteins/therapeutic use[MESH]|Treatment Outcome[MESH] |